[{"id":"110ceac2-d13a-400d-b118-27479465873a","acronym":"GLYRad","url":"https://clinicaltrials.gov/study/NCT02364206","created_at":"2021-01-18T11:15:23.364Z","updated_at":"2024-07-02T16:36:56.921Z","phase":"Phase 1/2","brief_title":"Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT02364206 - GLYRad","lead_sponsor":"Centre Jean Perrin","biomarkers":" PTEN • IDH1","pipe":"","alterations":" ","tags":["PTEN • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • ralimetinib (LY 2228820)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2015","start_date":" 06/08/2015","primary_txt":" Primary completion: 08/01/2019","primary_completion_date":" 08/01/2019","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2019-08-14"},{"id":"fa0366b2-b77f-4189-a5a6-884d66f42b34","acronym":"","url":"https://clinicaltrials.gov/study/NCT02860780","created_at":"2021-01-18T14:02:35.003Z","updated_at":"2024-07-02T16:37:04.664Z","phase":"Phase 1","brief_title":"A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer","source_id_and_acronym":"NCT02860780","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368) • ralimetinib (LY 2228820)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 08/10/2016","start_date":" 08/10/2016","primary_txt":" Primary completion: 05/15/2017","primary_completion_date":" 05/15/2017","study_txt":" Completion: 05/15/2017","study_completion_date":" 05/15/2017","last_update_posted":"2018-12-14"}]